IMDX Overview

Insight Molecular Diagnostics Inc., formerly Oncocyte Corporation, is a molecular diagnostics technology company. The Company's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The Company's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.

Wall Street analysts forecast IMDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMDX is8.50 USD with a low forecast of 8.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Insight Molecular Diagnostics Inc revenue for the last quarter amounts to 1.14M USD, decreased -23.35

Insight Molecular Diagnostics Inc. EPS for the last quarter amounts to -0.72 USD, decreased -62.50

Insight Molecular Diagnostics Inc (IMDX) has 55 emplpoyees as of April 05 2026.

Today IMDX has the market capitalization of 120.95M USD.